Duygu Ercan Uzundal

Duygu Ercan Uzundal

Auto-generated profile, based on publicly available information

Duygu Ercan Uzundal

Ankara Bilkent City Hospital

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
NANargiz Majidova Altuntash
Nargiz Majidova Altuntash
SYSendag Yaslikaya
Sendag Yaslikaya
MMMartin Mildanoğlu
Martin Mildanoğlu
ACAlper Coskun
Alper Coskun
DUDuygu Ercan Uzundal
Duygu Ercan Uzundal
OKOsman Köstek
Osman Köstek
Background/Aims: The treatment of hepatocellular carcinoma (HCC), which accounts for 90% of all liver cancers, is highly varied. The use of second-line treatments following progression on first-line atezolizumab and bevacizumab (Atez/Bev) for advanced HCC remains controversial. The aim of this study was to analyze the real-world clinical results of second-line treatments in progression after Atez/Bev and to determine the factors affecting prognosis. Materials and Methods: Fifty-eight patients treated with second-line sorafenib, regorafenib, and cabozantinib for progression after first-line Atez/Bev for advanced/metastatic HCC from 20 centers in Türkiye between October 2020 and June 2024 were retrospectively analyzed. Responses were evaluated by Response criteria, specifically Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria. Median overall survival (OS) and progression-free survival (PFS) were computed with the Kaplan–Meier method. The Cox regression model was utilized to analyze multivariate analyses. Results: About 82.8% of the patients were male and the median age of the whole group was 62 (range, 18-78) years. All patients progressed after first-line Atez/Bev and were given second-line treatment. The most commonly used second-line treatment option was sorafenib (70.7%), followed by regorafenib (12.1%) and cabozantinib (10.3%). Both median PFS (4.1 months) and median OS (7.8 months) were longer in patients treated with sorafenib compared to other treatments. In univariate analyses, Child–Pugh score B, alpha-fetoprotein (AFP) levels (>200 ng/mL), extrahepatic spread, and Prognostic Nutritional Index (PNI) < 47.6 substantially raised the risk of overall mortality. Multivariate analysis showed that extrahepatic spread (HR (Hazard ratio): 0.41, P = .012), PNI level (HR: 0.24, P =.005), and AFP level (HR:1.97, P = .049) were independent predictors of OS. Conclusion: Although second-line therapies after Atez/Bev show different degrees of efficacy, survival rates are consistent with the literature. Extrahepatic spread, AFP level, and PNI level are the main prognostic factors. In light of this information, personalized treatment strategies may improve outcomes for this challenging patient group. Cite this article as: Majidova N, Yaslıkaya S, Mıldanoglu MM, et al. Efficacy of second-line treatments after atezolizumab and bevacizumab in advanced hepatocellular carcinoma and related prognostic factors: A multicenter study by the turkish oncology group (TOG). Turk J Gastroenterol. 2025;36(5):293-301.

9 November 2026 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
DUDuygu Ercan Uzundal
Duygu Ercan Uzundal

25 October 2025 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
ATAlper Türkel
Alper Türkel
DUDuygu Ercan Uzundal
Duygu Ercan Uzundal
FGFatih Gürler
Fatih Gürler
İOİlknur Deliktaş Onur
İlknur Deliktaş Onur
SGSerkan Gülcü
Serkan Gülcü
ÜAÜlkü Yalçıntaş Arslan
Ülkü Yalçıntaş Arslan
Aims: This study aimed to evaluate responses to first- and second-line treatments, survival outcomes, and potential factors affecting survival in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). Methods: This retrospective study included 42 patients with metastatic GEP-NEC from three centers. First and second-line chemotherapy regimens were examined. The median progression-free survival (mPFS1 and mPFS2) for first and second-line treatments and overall survival (mOS) were evaluated. The effects of CRP levels, LDH levels, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) on survival were investigated as potential prognostic factors. Results: Median follow-up was 15 months (3-113). mPFS1 was 5 months (95% CI: 2.88-7.11) and mPFS2 was 2 months (95% CI: 1.67-2.32). The mOS was 15 months (95% CI: 10.90-19.09). Curative surgery patients had a 28-month mOS, and patients who could not undergo surgery had a mOS of 14 months (p=0.010). Patients with NLR


11 November 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
DUDuygu Ercan Uzundal
Duygu Ercan Uzundal

16 November 2026
Verified
Book
Closed access
ASAbdullah Sakin
Abdullah Sakin
EÖEsra Özer
Esra Özer
ATAli Türker
Ali Türker
EUEsma Uğuztemur
Esma Uğuztemur
HKHayrani Kaya
Hayrani Kaya
IÇİsMet Çulcuoğlu
İsMet Çulcuoğlu